<DOC>
	<DOC>NCT02062190</DOC>
	<brief_summary>Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?</brief_summary>
	<brief_title>Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia</brief_title>
	<detailed_description>Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Men 1865 years old, diagnosed with schizophrenia according to DSMIV and ICD10, which are in clozapine medication for at least 6 months. Patients will be excluded from the study: Have a diagnosis of diabetes Use other antipsychotic drugs, clozapine beyond Using medicines for diabetes or dyslipidaemia Accept not participate in any stage of the research.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>